Therapeutic gain by radiotherapy can be achieved through improved targeting, selectively sensitizing malignant cells, or protecting normal tissue. The majority of synthetic chemical radiation sensitizers and normal tissue protectors have proved to be too toxic at effective clinical doses. However, Asian botanicals (from both Chinese and Ayurvedic medicine) are being evaluated for their ability to improve therapeutic gain through the modulation of reactive oxygen species. An increase in the efficacy of radiotherapy on tumor tissue allows a reduction in the dose applied to normal tissues. In addition, some botanicals may selectively protect normal tissue or increase its repair following radiation therapy. The results are promising enough to consider clinical trials.
The Concept of Therapeutic Gain
The concept of therapeutic gain in radiation oncology is to increase the degree of tumor damage while minimizing the acute and chronic damage to surrounding normal tissues. This is primarily achieved by physical techniques that target the tumor and restrict the dose to defined normal tissues. Outcomes have improved since the development of highenergy radiation, inverse planning systems, intensity-modulated radiotherapy, and image-guided radiotherapy applications. Localizing techniques and fractionated radiotherapy (which allow radiation damage repair and repopulation of new cells) have considerably improved the therapeutic gain. Fractionation also allows reoxygenation and can induce cell cycle synchronization, both of which can be further enhanced by sensitizers. The potential to improve therapeutic gain may be achieved through the development of selective radiosensitizers and protectors. The pharmacological properties of these compounds can enable them to be differentially distributed or activated between tumor and normal tissues and to have selective metabolic effects. Because of their toxicity, very few of the chemical compounds have established clinical indications. The most promising radioprotectors have been the sulfhydryls. More than 5000 compounds were synthesized and screened by the Walter Reed Army Institute after World War II. 1, 2 Only amifostine-WR-2721 or S-2-(3-aminopropylamino) ethyl phosphorothioic acid-a sulfhydryl prodrug with reduced activation by malignant tissue, has been approved by the FDA for bone marrow and salivary gland protection, and it too has some unacceptable toxicity. 3 Ionizing radiation is electromagnetic radiation that possesses sufficient energy to induce ionization. Low-linearenergy-transfer radiation, such as X irradiation, is sparsely ionizing and results in the formation of reactive oxygen species and reactive nitrogen species that can damage biological molecules that include DNA, lipids, and proteins. This process enables opportunities for therapeutic gain by quenching these free radicals in normal tissues and enhancing their effects in malignant tissue. Radiomodulators are agents that modify the radiation response and include both synthetic chemicals and compounds derived from botanicals. Radiosensitizers are "compounds that when combined with radiation will achieve greater tumour inactivation than would have been expected from the additive effect of each modality (p. 42)." 4 They can also be defined as "agents that do not have a therapeutic effect of their own, but act to enhance the therapeutic effect of radiation(p. 151)." 5 Most synthetic radiosensitizers have proved too toxic to be used at effective clinical doses. Recent developments have focused on treatment with irradiation combined with chemotherapy drugs and targeted antibody or tyrosine kinase antagonists-an effective strategy that is often simply additive and does not necessarily spare normal tissues. Radioprotectors are "compounds that protect against radiation damage to targeted normal cells, but do not provide similar protection to tumour cells." 4 Normally, only agents administered preirradiation are considered radioprotectors. Those that are administered after irradiation to reduce toxicity are termed radiorecovery agents. Mitigators are agents that are administered both during and after irradiation but before manifestation of radiation injury, whereas a "radiation therapeutic" is an agent administered after the emergence of clinical problems. 6 The measurement of radiation damage can be through chemical, genetic, and biological assays that measure glutathione (GSH), glutathione-s-transferase (GST), glutathione peroxidase (GPx), superoxide dismutase (SOD), micronuclei, chromatid breaks, clastogenic factors (lipid peroxides), surviving CFUs (cell colony forming units) of gastrointestinal epithelium, bone marrow, human peripheral blood lymphocytes as well as through symptoms of radiation sickness and death rates in animal studies. Evaluating relative damage between tumor and normal tissues in animal studies can follow these screening assays.
More recently, new avenues have been explored to improve therapeutic gain from radiotherapy. One approach is to use antiangiogenic agents to improve tumor reoxygenation without increasing normal tissue toxicity. Many botanicals display antiangiogenic as well as other multitargeted effects that can reverse radiation-induced hypoxic factor and prevent metastases. 7 New evidence suggests that radiation may expose tumor antigen and, together with immune-enhancing adjuvants, can function as a vaccine. Many Asian herbs display immune-enhancing activities 8 and could result in both a beneficial local effect as well as an abscopal effect when combined with radiotherapy. 9 Unfortunately, our methodology for evaluating therapeutic gain in humans with cancer is limited, but new functional imaging techniques using SPECT (single photon emission computed tomography) and PET nuclear medicine scans or nuclear magnetic resonance are promising. Minimal research has been done with botanicals (herb or plant-derived products) despite the fact that some manifest interesting radiosensitizing and radioprotecting properties when evaluated in the laboratory. Because both Chinese and Ayurvedic herbs have a common source and similar roots in traditional medicine, I will discuss the preclinical properties of these compounds under the title of Asian herbs or botanicals. I will use their Western botanical categorization and describe their potential therapeutic use from a Western medicine approach rather than through the challenging complexities of traditional medicine. I refer the reader to the original referenced reports for details regarding species categorization, plant parts, source, specific extracts, and exact assay methodology. These details can fundamentally change experimental and therapeutic outcome. Not surprisingly, there are very few quality randomized clinical trials using these botanicals or their derivatives. Although I can postulate possibilities from traditional experience, clearly, they have not been used in the context of modern radiotherapy and chemotherapy until very recently. The challenge in using Asian botanicals in Western oncology is to use quality-assured products, verified by both chemical spectrographs (fingerprints) and biological assays; to determine the advantages of single-agent extraction versus complex mixtures; and to direct the promising agents though appropriate preclinical efficacy and toxicity studies, prior to phase I to III clinical trials.
Botanical Radiosensitizers and Radioprotectors That Modulate Reactive Oxygen Intermediates (ROIs) and Associated Genes
Potential botanical radiosensitizers are listed in Table 1 and radioprotectors are listed in Table 2 . They are reviewed in more detail elsewhere. [97] [98] [99] [100] However, the differentiation between sensitizing and protecting may depend on the administered dose, tissue type, local environmental factors (eg, oxygenation status, pH, antioxidant to pro-oxidant ratio, etc), and fractionation of X irradiation. How do these botanicals interact with radiotherapy? Molecular biology research has shown that radiotherapy induces gene expression of NF-kB and TNF (tumor necrosis factor). 101 These are potent inducers of both proapoptotic and prosurvival pathways that contribute to both tumor cell death and to the development of resistance. The induction results from the generation of ROIs. 102 In turn, NF-kB and TNF alter the membrane permeability of mitochondria, leading to cytochrome c release and caspase activation, resulting in apoptosis. In contrast, NF-kB also mediates prosurvival signaling through regulation of genes involved in cellular survival (Bcl-2, COX-2, inhibitor of apoptosis protein or IAP, and SOD). 97 This polar effect is not clearly understood but may depend on other molecular and physiological conditions that differ between the tumor and normal tissue. A differential enhancement of the shift by administration of botanicals could result in increased cell survival in normal tissue (resistance to radiotherapy) compared with increased sensitivity in the tumor (sensitization to radiotherapy); Figure 1 .
The final degree of damage between tumor and normal tissue depends on many complex variables. 103 Approximately two thirds of DNA damage is caused by short-lived (nanoseconds to microseconds) high-energy primary and secondary free radicals. Most will be quenched rapidly outside of the high-dose target. To act as a radioprotector by scavenging these free radicals, an antioxidant botanical or vitamin needs to be present in sufficient concentrations and have efficient radical scavenging capabilities in proximity to the target (DNA) during the radiation exposure. The free-radical generation in tissues may continue after the radiation exposure as a consequence of an inflammatory response, with the generation of cytokines and sustained production of longer-lived free radicals. 104 In this setting, particularly in normal tissues, antioxidant botanicals could be quite effective in protecting against sustained free-radical damage. As previously mentioned, free radicals can also serve as initiators for complex signal transduction and gene expression pathways governing prosurvival and antisurvival responses. Whe ther there is a differential inflammatory response in tumors is less clear, given their markedly different redox status. The situation of administering an antioxidant agent is further complicated by the level attained by the agent in the surrou nding environment and the effect it can have on altering the antioxidant effects of many molecules. For example, b-carotene is an antioxidant at low oxygen concentrations, but it acts as a pro-oxidant at high oxygen concentrations. 105 The lack of reliable methods to predict the relative responses to irradiation of the tumor compared with normal tissue, in the presence of antioxidants, has led to caution in the administration of these agents, which cannot be relaxed until we have derived scientific methods to evaluate and predict response. 106, 107 Some interesting avenues are being explored to correlate oncogene activity and ROI generation as well as the differential responses of tumor and normal tissue to antioxidants. There is a significant positive correlation between COX-2 expression and catalase (CAT) activity in normal tissue and an inverse trend between p53 expression and SOD and catalase activity in tumor tissue. In addition, patients with overexpressed p53 protein levels have lower GPx enzyme levels in normal tissues and the converse in tumor tissue. 108 Administration of manganese SOD-plasmid liposomes (MnSOD-PL) provides radiation protection mediated by MnSOD stabilization of the antioxidant pool, including GSH and total thiols in normal tissues. Animal experiments with orthotopic squamous cell tumors demonstrated paradoxical and beneficial tumor radiosensitization following intratracheal or intraoral MnSOD-PL, respectively. The mechanism of MnSOD-PL tumor radiosensitization may involve a difference in redox balance between tumors and normal tissues. Differences in handling radiation-induced oxidative stress between tumors and normal tissues can provide a fundamental basis to design new cancer therapeutic agents that can exploit differences in mechanisms of handling the oxidative stress of ionizing radiation damage between normal tissue and tumors. 109 Agents that activate or support the antioxidant systems could enhance both tumor cell death and protect normal tissues. Clinical evaluation of this postulate is quite limited, mainly because of the fear that the efficacy of standard therapy would be reduced. Although we must be cautious, so far any adverse effect on tumor control has been in smokers in whom antioxidants seem to develop pro-oxidant characteristics that leave this unique population susceptible to second primary tumors. 110, 111 Treatment with antioxidant botanicals as an adjuvant therapy added to radiotherapy could protect the normal tissues against radiation-induced side effects, whereas other properties can increase tumor cell kill, either through conversion to pro-oxidant properties or via multiple targeting interactions with cell signaling pathways and modulation of genomic expression. Optimization of complex chemical mixtures would be a novel approach compared with the standard of isolating a single index chemical for therapy. Various cellular defense mechanisms such as the antioxidant vitamins and enzyme systems are normally induced in response to excessive ROIs, but they become overburdened during radiotherapy, potentially increasing late toxicity and suppressing mechanisms (such as the immune system) that reduce the spread of malignant cells. Some preliminary clinical studies with the Asian herbs Naturin 112 and Vitexina 113 provide some limited support for reduced toxicity.
Future Research
Most research is currently at the preclinical stage. Better quality assurance, safety, and validation of both chemical content and consistent biological activities are required prior to resource-intensive clinical trials. Although many of these botanicals have been used traditionally in Chinese and Ayurvedic medicine, we require more validation in the Figure 1 . Potential role of botanicals to improve therapeutic gain in tumor compared with normal tissue via differential polar outcomes from proapoptotic compared with antiapoptotic signaling induced by radiation-generated reactive oxygen intermediates context of modern therapies, such as radiotherapy, using current scientific standards.
The lack of worldwide regulation of botanicals and their derivatives raises uncertainty with each product. There is wide variation in the composition of similar botanical agents. Even within the same species, biological variation caused by differences in soil conditions, moisture, temperature, and harvesting conditions may lead to considerable variability in the concentrations of the bioactive constituents. Activity of the botanical may vary among the capsule, powder, and suspension forms. The formulation used in both the preclinical experiments and the clinical trial needs to be precisely stated and should be a validated and verified identical preparation. Stability testing at regular intervals throughout the conduct of the studies is recommended to ensure that the product retains its potency. Quality testing to ensure minimally acceptable tolerances with regard to heavy metal content, bacterial and fungal counts, pesticide residues, and potential contamination with prescription pharmaceuticals is mandatory for clinical use. Chromatographic fingerprint analysis may be used for determining the identity, stability, and consistency of botanicals as well as the identification of adulterants. 114 Natural health products differ from pharmaceutical compounds in that they consist of complex mixtures of chemicals. The polypharmacy of complex botanicals may provide distinct advantages over single-ingredient drugs because they contain a major chemical that acts synergistically with secondary compounds. In addition, the secondary compounds may mitigate the undesirable side effects caused by the predominant active ingredients. Multiple ingredients could act through multiple discrete pathways to therapeutically affect the host. Lower concentrations of each of the botanicals may therefore be more efficacious when used together than when used individually. These theories could explain and justify complex botanical actions, but there is a dearth of studies done to demonstrate the mechanisms of action and authenticity of therapeutic usages of complex mixtures, and it is challenging to predict whether there is therapeutic gain or loss. 115 Many preclinical screening studies, directed by intuition and observation of traditional health systems, such as Chinese and Ayurvedic medicine, reveal that many plants exhibit a diverse array of biological activities that may be relevant to the mitigation of ionizing radiation-induced damage in normal tissues of humans. However, so far, only a fraction of these plants have been investigated. There is an urgent need to develop newer, more efficient, and reliable bioassays for large-scale rapid evaluation of both the radiosensitizing and radioprotective efficacies of plant extracts; to systematically evaluate this efficacy using standardized extracts; and to identify the bioactive compounds responsible for their potential therapeutic effects. Isolation of the bioactive constituents and subsequent combination in appropriate proportions may further potentiate the effects of herbal preparations to protect normal tissues and to enhance the tumoricidal effect of radiotherapy. Animal models show that there is usually a window of opportunity about 30 minutes to 2 hours prior to irradiation, when the administration of appropriate herbal preparations provides maximum therapeutic gain. There is also a need to investigate formulations that can also be of use in the postirradiation period. Recent evidence suggests a polar effect for some so-called radiosensitizers and radioprotectors, in which their differential effects on tumors and normal tissues can result in a therapeutic gain. Many of the botanicals demonstrate additional multitargeting activities such as antiangiogenesis and immunomodulation. Either additive, synergistic, or adverse interactions could occur. Both reliable preclinical and clinical predictors of therapeutic gain are required. Clinical trials have not yet been undertaken with most of these herbal radiobiological modifiers. It will be important to develop a model based on sound ethnopharmacological and radiobiological scientific principles with appropriate quality assurance.
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